Virus Diseases

0
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Plus Therapeutics
2 programs
Exposed to a SARS-CoV-2 infectionN/A1 trial
Exposed to a SARS-CoV-2 infectionN/A1 trial
Active Trials
NCT05606198CompletedEst. Jun 2023
NCT05074953CompletedEst. Dec 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Plus TherapeuticsExposed to a SARS-CoV-2 infection
Plus TherapeuticsExposed to a SARS-CoV-2 infection

Clinical Trials (2)

NCT05606198Plus TherapeuticsExposed to a SARS-CoV-2 infection

Post-COVID-19 Monitoring in Routine Health Insurance Data With Focus on Autoimmune Diseases (POINTED-AD)

Start: May 2022Est. completion: Jun 2023
N/ACompleted
NCT05074953Plus TherapeuticsExposed to a SARS-CoV-2 infection

Post-COVID-19 Monitoring in Routine Health Insurance Data

Start: Aug 2021Est. completion: Dec 2023
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space